• Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors | Morningstar

    المصدر: Buzz FX / 18 سبتمبر 2024 10:06:12   America/New_York

    N/A
شارك على،